Eqis Capital Management Inc. Sells 458 Shares of Illumina, Inc. (NASDAQ:ILMN)
Eqis Capital Management Inc. decreased its position in Illumina, Inc. (NASDAQ:ILMN) by 5.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,224 shares of the life sciences company’s stock after selling 458 shares during the quarter. Eqis Capital Management Inc.’s holdings in Illumina were worth $3,028,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Mitsubishi UFJ Asset Management UK Ltd. raised its stake in shares of Illumina by 35.3% in the second quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 11,500 shares of the life sciences company’s stock worth $4,234,000 after buying an additional 3,000 shares during the period. Covenant Asset Management LLC raised its stake in shares of Illumina by 2.2% in the second quarter. Covenant Asset Management LLC now owns 7,546 shares of the life sciences company’s stock worth $2,778,000 after buying an additional 161 shares during the period. Toth Financial Advisory Corp bought a new position in shares of Illumina in the second quarter worth about $313,000. Waverton Investment Management Ltd raised its stake in shares of Illumina by 61.2% in the second quarter. Waverton Investment Management Ltd now owns 164,266 shares of the life sciences company’s stock worth $60,475,000 after buying an additional 62,360 shares during the period. Finally, NEXT Financial Group Inc raised its stake in shares of Illumina by 21,390.0% in the second quarter. NEXT Financial Group Inc now owns 2,149 shares of the life sciences company’s stock worth $791,000 after buying an additional 2,139 shares during the period. Institutional investors and hedge funds own 90.48% of the company’s stock.
Several research firms have recently commented on ILMN. Zacks Investment Research downgraded GasLog Partners LP Unit from a “hold” rating to a “strong sell” rating in a research note on Tuesday, April 2nd. Deutsche Bank raised their price objective on Spirit Airlines from $75.00 to $79.00 and gave the stock a “buy” rating in a research note on Friday, July 12th. ValuEngine downgraded Vereit from a “buy” rating to a “hold” rating in a research note on Friday, July 19th. Wolfe Research began coverage on Waters in a research note on Thursday, May 30th. They issued an “underperform” rating on the stock. Finally, Bank of America set a $80.00 price objective on Colgate-Palmolive and gave the stock a “buy” rating in a research note on Friday, July 12th. One analyst has rated the stock with a sell rating, four have given a hold rating and twelve have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $332.77.
Illumina (NASDAQ:ILMN) last issued its earnings results on Monday, July 29th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.32 by $0.03. The company had revenue of $838.00 million for the quarter, compared to the consensus estimate of $835.12 million. Illumina had a return on equity of 23.49% and a net margin of 25.06%. The firm’s quarterly revenue was up 1.0% on a year-over-year basis. During the same quarter last year, the company earned $1.43 EPS. Equities analysts predict that Illumina, Inc. will post 6.34 EPS for the current fiscal year.
In other Illumina news, Director Jay T. Flatley sold 3,300 shares of the firm’s stock in a transaction that occurred on Wednesday, July 24th. The stock was sold at an average price of $304.00, for a total transaction of $1,003,200.00. Following the completion of the transaction, the director now owns 269,316 shares in the company, valued at approximately $81,872,064. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert S. Epstein sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $310.44, for a total value of $1,552,200.00. Following the transaction, the director now owns 8,256 shares of the company’s stock, valued at approximately $2,562,992.64. The disclosure for this sale can be found here. Insiders have sold a total of 69,291 shares of company stock valued at $22,420,366 in the last 90 days. 0.38% of the stock is currently owned by company insiders.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Recommended Story: What are CEFs?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.